Imaging The Hepatitis C Virus Life Cycle In Real-time
Funder
National Health and Medical Research Council
Funding Amount
$477,504.00
Summary
Hepatitis C virus (HCV) is a serious viral pathogen that causes significant liver disease. This proposal plans to examine how two proteins from the HCV, core and NS5A, interact with host proteins and pathways to facilitate viral replication and release of HCV; two processes that are poorly understood. Specifically we will tag viral proteins to allow us to investigate the HCV life cycle in living cells and determine the role of core and NS5A in facilitating HCV replication. This proposal may unco ....Hepatitis C virus (HCV) is a serious viral pathogen that causes significant liver disease. This proposal plans to examine how two proteins from the HCV, core and NS5A, interact with host proteins and pathways to facilitate viral replication and release of HCV; two processes that are poorly understood. Specifically we will tag viral proteins to allow us to investigate the HCV life cycle in living cells and determine the role of core and NS5A in facilitating HCV replication. This proposal may uncover novel therapeutic strategies to combat HCV.Read moreRead less
Regulation Of Secretion Of The Fungal Virulence Determinant, Phospholipase B
Funder
National Health and Medical Research Council
Funding Amount
$487,500.00
Summary
Serious systemic infections due to fungi have increased dramatically in the past few years, especially in people with poorly functioning immune systems. Treatment of these conditions is problematic because the few drugs which are available are not highly effective, and-or cause significant side-effects. Little is understood of how fungi cause disease, and this problem must be addressed if these infections are to be contained. We have discovered that the enzyme, phospholipase B (PLB), is secreted ....Serious systemic infections due to fungi have increased dramatically in the past few years, especially in people with poorly functioning immune systems. Treatment of these conditions is problematic because the few drugs which are available are not highly effective, and-or cause significant side-effects. Little is understood of how fungi cause disease, and this problem must be addressed if these infections are to be contained. We have discovered that the enzyme, phospholipase B (PLB), is secreted by the disease-causing fungus, Cryptococcus neoformans, and that it is important in enabling the fungus to invade the host's cells and spread around the body from the lungs to the brain, where it can cause meningoencephalitis. PLB is also produced by other disease-causing fungi. The mechanism of PLB secretion is completely unknown. In this project we aim to determine the pathways involved in PLB secretion with the intention of exploiting steps unique to pathogenic fungi, for the future design of new anti-fungal drugs.Read moreRead less
Inflammatory Mediators Of Liver Injury In Chronic Hepatitis C
Funder
National Health and Medical Research Council
Funding Amount
$349,336.00
Summary
Presently, liver disease from chronic hepatitis C and obesity represents a major health problem. Overall, approximately 50% of Australians with chronic hepatitis C are obese and these patients are at significantly increased risk of rapidly progressing to liver failure. It is now recognized that fat derived factors play an important role in regulating inflammatory responses. This grant proposal aims to gain insight into how liver and fat derived inflammatory factors interact to promote increased ....Presently, liver disease from chronic hepatitis C and obesity represents a major health problem. Overall, approximately 50% of Australians with chronic hepatitis C are obese and these patients are at significantly increased risk of rapidly progressing to liver failure. It is now recognized that fat derived factors play an important role in regulating inflammatory responses. This grant proposal aims to gain insight into how liver and fat derived inflammatory factors interact to promote increased liver damage in chronic hepatitis C and obesity.Read moreRead less
Risk Of Hepatitis C Reinfection Among People With Current Injecting Drug Use Following Successful HCV Treatment
Funder
National Health and Medical Research Council
Funding Amount
$2,245,228.00
Summary
In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs ....In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs.Read moreRead less
SCALE-C: Strategies For Hepatitis C Testing And Treatment In Aboriginal Communities That Lead To Elimination
Funder
National Health and Medical Research Council
Funding Amount
$2,175,170.00
Summary
Prevalence of hepatitis C infection within the Aboriginal population is among the highest of any identifiable population in Australia. Highly effective, direct-acting antiviral (DAA) therapy, and their listing on the PBS in 2016 has revolutionised HCV clinical management in Australia. The SCALE-C study will evaluate an established test and treat model to rapidly scale-up DAA within four Aboriginal communities to determine both impact on community prevalence and ongoing transmission.
Individualising Care For Patients With Chronic Hepatitis C: Predicting Side Effects And Treatment Response Using Genomic And Proteomic Approaches.
Funder
National Health and Medical Research Council
Funding Amount
$55,575.00
Summary
Patients undergoing treatment for hepatitis C must endure a treatment characterized by unpredictable treatment side effects and uncertainty about the likelihood of cure. This project will investigate genetic predictors of treatment related side-effects and protein markers to predict treatment response. Better definition of the risks and benefits of therapy, may facilitate patients and clinicians to make more informed decisions about treatment, thus individualising treatment and potentially impro ....Patients undergoing treatment for hepatitis C must endure a treatment characterized by unpredictable treatment side effects and uncertainty about the likelihood of cure. This project will investigate genetic predictors of treatment related side-effects and protein markers to predict treatment response. Better definition of the risks and benefits of therapy, may facilitate patients and clinicians to make more informed decisions about treatment, thus individualising treatment and potentially improving the safety and efficacy of therapy.Read moreRead less
Invasive fungal infections are a serious, escalating health issue. They cause severe disease with high death rates and are very costly to the health system. Current drugs often have suboptimal efficacy and cause side effects. New drugs are needed urgently. Many fungi, including the AIDS-related pathogen, Cryptococcus neoformans, secrete phospholipase B (Plbp) to facilitate infection. We will identify and investigate the Plbp secretion pathway as a novel anti-fungal drug target.
Population-level Epidemiological Trends In Hepatocellular Carcinoma In Queensland 1996 - 2010.
Funder
National Health and Medical Research Council
Funding Amount
$251,695.00
Summary
Incidence and mortality of hepatocellular carcinoma (HCC, the most common form of liver cancer) is increasing in Australia, driven by viral hepatitis infections. Disease burden is not defined in Queensland, particularly for Indigenous, migrant and regional and remote communities. Such factors may influence risk of viral hepatitis, access to treatment, and incidence and survival of HCC. Defining disease burdens will enable clinical programs targeted at groups most at risk in order to impact HCC t ....Incidence and mortality of hepatocellular carcinoma (HCC, the most common form of liver cancer) is increasing in Australia, driven by viral hepatitis infections. Disease burden is not defined in Queensland, particularly for Indigenous, migrant and regional and remote communities. Such factors may influence risk of viral hepatitis, access to treatment, and incidence and survival of HCC. Defining disease burdens will enable clinical programs targeted at groups most at risk in order to impact HCC trends.Read moreRead less